膀胱Nephrogenic adenomaの2例(本邦報告例の文献的考察)

症例1は72歳女.尿管腫瘍に対する腎尿管全摘術8ヵ月後の膀胱鏡時に膀胱腫瘍を認めた.症例2は57歳女.5回のTUR-Btの後に計6回のBCG膀胱内注入療法を行い, その後の膀胱鏡で2個の膀胱腫瘍を認めた.2例ともTUR-Btを施行.組織学的診断では2例ともnephrogenic adenoma.今回の2例を含めて, これまで計39例の本症が我が国で報告されている.男21例, 女18例で平均年齢は56.5歳.おもな症状は血尿が16例と最多で, ついで頻尿が6例である.本症の誘因としては尿路の外科的手術が16例で, 尿路感染症が9例, BCG膀胱内注入療法が6例である.特にBCGが保険認可された1996年12月以降はBCG膀胱内注入療法に引き続いて起こる症例の比率が高くなっており, 将来的な膀胱nephrogenic adenomaの増加が予想されるIn the two cases we report here, tumors were diagnosed as nephrogenic adenoma by pathohistological examination. Case 1 was a 72-year-old female presenting with a bladder tumor 8 months after receiving ureteral tumor surgery. Transurethral resection of bladder tumor (TUR-Bt) was performed. Case 2 was a 57-year-old female who had received intravesical bacillus Calmette-Guerin (BCG) treatment 6 times after her fifth TUR-Bt. Two tumors were found by cystoscopy, and TUR-Bt was performed. There have been 39 cases of nephrogenic adenoma of the bladder reported in Japan; 21 were male and 18 female with a mean age of 56.5 years. The main complaint was hematuria, which was seen in 16 cases followed by pollakisuria in 6 cases. Nephrogenic adenoma occurred after surgery of the urinary tract in 16 cases, followed by urinary tract infection in 9 cases and intravesical BCG treatment in 6 cases. The ratio of cases occurring after intravesical BCG treatment has increased since BCG approval for bladder carcinoma treatment in December 1996 in Japan, and an increase in the number of cases is expected in the future